Sars-Cov-2 Breakthrough Infection and Death in Covid-19 Vaccines Recipients in North of Iran in 2021

Abstract

Rouhollah Shabestan, Behnam Amani, Bahman Amani, Arash Akbarzadeh, Maryam Zamani, Mohammad Reza Saeidi, Seyede Roghayeh Mirshojaee, Narjes Abdolmohammadi, Mohammad Reza Parsaie, Kourosh Rajabkhah, Vida Kardanmoghadam, Seyede Samaneh Momeni

Aim: This study aimed to assess the cases of SARS-CoV-2 breakthrough infection and death among, Sinopharm, Sputink V, Soberana, and COVAXIN vaccines receivers in Mazandaran.

Methods: This retrospective cohort study was involving 320260 cases who received fully vaccinated (two doses) with five types of COVID-19 vaccine (ChAdOx1 nCoV-19, Sinopharm, Sputink V, Soberana, and COVAXIN) between February 2021 to August 2021 in the Mazandaran province. The outcomes of interest were SARS-CoV-2 breakthrough infection and death due to COVID-19 after vaccination. Data were analyzed using R software.

Results: Among 320260 COVID-19 vaccine recipients, 712 (0.22%) cases of SARS-CoV-2 breakthrough infections were identified and 94 (0.029%) hospitalized patients died from COVID-19. The cases of SARS-CoV-2 breakthrough infections were in Sinopharm (0.26%), ChAdOx1 nCoV-19 (0.09%), Sputnik (0.21%) Soberana (0.01%) and Covaxin (0.38%), respectively. The cases of death in vaccine recipients in Sinopharm, AZD1222, Sputnik, Soberana, and Covaxin were 81, 11, 1, 1, and 0 cases, respectively. A significant difference was observed between COVID-19 vaccines in terms of death (P<0.05).

Conclusion: Based on the findings, the most cases of SARS-CoV-2 breakthrough infection and death were observed in Sinopharm vaccine receivers.

PDF